ASX 200 healthcare shares vastly outperformed their peers, rising 9.21%, as earnings season continued last week.
Pleasing FY26 reports from heavyweights CSL Ltd (ASX: CSL) and Pro Medicus Ltd (ASX: PME) turbocharged the sector.
The broader S&P/ASX 200 Index (ASX: XJO) slipped 0.62% over the week to 9,058.9 points on Friday.
Healthcare is in the middle of a rapid recovery following a 29% slump over the 12 months to early June.
The S&P/ASX 200 Health Care Index (ASX: XHJ) reached a 9-year low on 3 June.
The sector then pivoted as value investors rushed in to snap up blue-chips on the cheap.
Healthcare shares have skyrocketed 41% since 3 June, compared to a 3% rise for the ASX 200.
Let’s review some specifics from last week.
Healthcare shares led the ASX sectors last week
Last week, several major healthcare companies revealed their latest periodic earnings results.
The CSL share price leapt 23.3% to $168.30 on the strength of its FY26 results last week.
CSL shares have rocketed 82% since the healthcare sector rebound began on 3 June. Â
Pro Medicus shares jumped 7.1% to $191.60 on the back of the company’s FY26 report.
The Pro Medicus share price is up 20% since 3 June.Â
The Cochlear Ltd (ASX: COH) share price rose 1.4% to $135.48 following the hearing implant maker’s FY26 report.
Cochlear shares have increased 42% since 3 June.
The Healius Ltd (ASX: HLS) share price jumped 13.8% to 46 cents following its FY26 report last week.
Healius shares are up 38% since 3 June.
The EBOS Group Ltd (ASX: EBO) share price ascended 7.2% to $18.96 following the company’s FY26 results.
EBOS shares are up 20% since 3 June.
The Mesoblast Ltd (ASX: MSB) share price lifted 6.8% to $2.36 following a phase 3 trial update.
Mesoblast shares have risen 17% since 3 June. Â
ASX 200 market sector snapshot
Here’s how the 11 market sectors stacked up last week, according to CommSec data.
Over the five trading days:
| S&P/ASX 200 market sector | Change last week |
| Healthcare (ASX: XHJ) | 9.21% |
| Materials (ASX: XMJ) | 5.61% |
| Energy (ASX: XEJ) | 3.5% |
| Utilities (ASX: XUJ) | 0.85% |
| Communication Services (ASX: XTJ) | (1.41%) |
| Industrials (ASX: XNJ) | (2.08%) |
| Consumer Staples (ASX: XSJ) | (2.65%) |
| Information Technology (ASX: XIJ) | (3.57%) |
| A-REIT (ASX: XPJ) | (4.43%) |
| Financials (ASX: XFJ) | (5.11%) |
| Consumer Discretionary (ASX: XDJ) | (6.55%) |
The post ASX 200 healthcare shares soar 9% amid notable FY26 reports from CSL, Pro Medicus appeared first on The Motley Fool Australia.
Wondering where you should invest $1,000 right now?
When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for over ten years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
Scott just revealed what he believes could be the ‘five best ASX stocks’ for investors to buy right now. We believe these stocks are trading at attractive prices and Scott thinks they could be great buys right nowâ¦
* Returns as of 1 August 2026
.custom-cta-button p {
margin-bottom: 0 !important;
}
More reading
- Here are the top 10 ASX 200 shares today
- 16 ASX 200 shares with ex-dividend dates next week
- 3 ASX 200 stocks, including CSL, leaping 15% to 23% in this week’s sliding market
- 8 ASX shares just upgraded by the experts
- Why Guzman Y Gomez, Pro Medicus and James Hardie shares are turning heads on Friday
Motley Fool contributor Bronwyn Allen has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended CSL and Cochlear. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has recommended Pro Medicus. The Motley Fool Australia has recommended CSL, Cochlear, and Pro Medicus. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.